CN117769422A - 治疗与监测帕金森病的方法 - Google Patents

治疗与监测帕金森病的方法 Download PDF

Info

Publication number
CN117769422A
CN117769422A CN202280037732.0A CN202280037732A CN117769422A CN 117769422 A CN117769422 A CN 117769422A CN 202280037732 A CN202280037732 A CN 202280037732A CN 117769422 A CN117769422 A CN 117769422A
Authority
CN
China
Prior art keywords
compound
subject
disease
administered
lrrk2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280037732.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·L·詹宁斯
V·M·达里亚尼
S·亨特沃尔克-罗德里格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CN117769422A publication Critical patent/CN117769422A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN202280037732.0A 2021-04-30 2022-04-29 治疗与监测帕金森病的方法 Pending CN117769422A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182207P 2021-04-30 2021-04-30
US63/182,207 2021-04-30
PCT/US2022/026898 WO2022232487A1 (en) 2021-04-30 2022-04-29 Methods for treating and monitoring parkinson's disease

Publications (1)

Publication Number Publication Date
CN117769422A true CN117769422A (zh) 2024-03-26

Family

ID=83847331

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280037732.0A Pending CN117769422A (zh) 2021-04-30 2022-04-29 治疗与监测帕金森病的方法

Country Status (9)

Country Link
US (1) US20240207266A1 (https=)
EP (1) EP4329763A4 (https=)
JP (1) JP2024515885A (https=)
CN (1) CN117769422A (https=)
AU (1) AU2022267325A1 (https=)
CA (1) CA3217230A1 (https=)
MX (1) MX2023012851A (https=)
TW (1) TW202308635A (https=)
WO (1) WO2022232487A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118878521A (zh) * 2024-09-26 2024-11-01 苏州美诺医药科技有限公司 一种lrrk2抑制剂的制备方法
CN119119035A (zh) * 2024-08-30 2024-12-13 中山大学 一种ripk1激酶靶点抑制剂及其制备方法与应用
WO2026002197A1 (zh) * 2024-06-28 2026-01-02 成都康弘药业集团股份有限公司 一种治疗或预防lrrk2介导的疾病的化合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051214A1 (zh) * 2023-09-07 2025-03-13 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102091895B1 (ko) * 2012-05-03 2020-04-14 제넨테크, 인크. 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
WO2014059052A1 (en) * 2012-10-09 2014-04-17 Uab Research Foundation Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism
SMT202100699T1 (it) * 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002197A1 (zh) * 2024-06-28 2026-01-02 成都康弘药业集团股份有限公司 一种治疗或预防lrrk2介导的疾病的化合物
CN119119035A (zh) * 2024-08-30 2024-12-13 中山大学 一种ripk1激酶靶点抑制剂及其制备方法与应用
CN118878521A (zh) * 2024-09-26 2024-11-01 苏州美诺医药科技有限公司 一种lrrk2抑制剂的制备方法

Also Published As

Publication number Publication date
EP4329763A1 (en) 2024-03-06
CA3217230A1 (en) 2022-11-03
TW202308635A (zh) 2023-03-01
EP4329763A4 (en) 2025-03-05
MX2023012851A (es) 2024-03-19
AU2022267325A1 (en) 2023-11-16
WO2022232487A1 (en) 2022-11-03
US20240207266A1 (en) 2024-06-27
JP2024515885A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
CN117769422A (zh) 治疗与监测帕金森病的方法
Balu et al. Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's disease
Chen et al. Metabolomics reveals metabolite changes of patients with pulmonary arterial hypertension in China
ES2731678T3 (es) Herramientas de diagnóstico para la enfermedad de Alzheimer
Mollá et al. Modulators of neuroinflammation have a beneficial effect in a Lafora disease mouse model
Nakanishi et al. Prostaglandin transporter (PGT/SLCO2A1) protects the lung from bleomycin-induced fibrosis
US20170184614A1 (en) Methylated Peptides Derived from Tau Protein and their Antibodies for Diagnosis and Therapy of Alzheimer's Disease
ES2870851T3 (es) Método para detectar enfermedades musculares degenerativas y método para determinar la eficacia terapéutica sobre las enfermedades
US20130251731A1 (en) Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
WO2019089988A1 (en) Isoindoline compositions and methods for treating neurodegenerative disease
Salort et al. Regulation of cannabinoid CB1 and CB2 receptors, neuroprotective mTOR and pro-apoptotic JNK1/2 kinases in postmortem prefrontal cortex of subjects with major depressive disorder
Ogawa et al. Altered ethanolamine plasmalogen and phosphatidylethanolamine levels in blood plasma of patients with bipolar disorder
Zhao et al. Branched-chain amino acids contribute to diabetic kidney disease progression via PKM2-mediated podocyte metabolic reprogramming and apoptosis
Zeleznik et al. Plasma metabolomics of primary open-angle glaucoma in three prospective US cohorts and the UK Biobank
Siddik et al. Branched-chain amino acids are linked with Alzheimer’s disease-related pathology and cognitive deficits. Cells. 2022; 11 (21): 3523
US20240295566A1 (en) Method for diagnosing and treating metabolic disorders
Sang et al. Thiamine pyrophosphokinase-1 deficiency in neurons drives Alzheimer’s multiple pathophysiological alterations
JP2026507930A (ja) グルコセレブロシダーゼアクチベータを使用した患者におけるパーキンソン病の処置
Bagchi Development and use of LC-MS/MS methods to study the brain dynamics of major monoamines and the pharmacokinetics of dual norepinephrine and serotonin reuptake inhibitors in the mouse
Metallo et al. Hepatic serine and lipid metabolism drive diabetic peripheral neuropathy
Mullins et al. Branched-Chain Amino Acids Are Linked with Alzheimer’s Disease-Related Pathology and Cognitive Deficits
WO2023174946A1 (en) Early and non-invasive method for assessing a subject's risk of having parkinson's disease
Hagos The Role of Membrane Transporters in Traumatic Brain Injury: Interventional and Genetic Investigations
Fraser Novel biomarkers for Parkinson disease
Qu et al. Beta-Amyloid Auto-antibodies are reduced in Alzheimer's

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination